{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T13:27:09Z","timestamp":1746883629387},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,18]]},"DOI":"10.7759\/cureus.67113","type":"journal-article","created":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T08:46:57Z","timestamp":1723970817000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Erenumab on Migraine Disability: A Three-Month MIDAS (Migraine Disability Assessment Scale) Score Analysis at Dubai Health Facilities"],"prefix":"10.7759","author":[{"given":"Ali","family":"Almarzooqi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwan","family":"Zidan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2001.041007646.x","article-title":"Prevalence and burden of migraine in the United States: data from the American Migraine Study II","volume":"41","author":"Lipton RB","year":"2001","unstructured":"Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001, 41:646-57. 10.1046\/j.1526-4610.2001.041007646.x","journal-title":"Headache"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252808.97649.21","article-title":"Migraine prevalence, disease burden, and the need for preventive therapy","volume":"68","author":"Lipton RB","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007, 68:343-9. 10.1212\/01.wnl.0000252808.97649.21","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00483.x","article-title":"Calcitonin gene-related peptide (CGRP) and migraine","volume":"46","author":"Durham PL","year":"2006","unstructured":"Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006, 46:S3-8. 10.1111\/j.1526-4610.2006.00483.x","journal-title":"Headache"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"Goadsby PJ","year":"1993","unstructured":"Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993, 33:48-56. 10.1002\/ana.410330109","journal-title":"Ann Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399411002067","article-title":"Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation","volume":"13","author":"Raddant AC","year":"2011","unstructured":"Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011, 13:e36. 10.1017\/S1462399411002067","journal-title":"Expert Rev Mol Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1756286420927119","article-title":"The role of erenumab in the treatment of migraine","volume":"13","author":"Andreou AP","year":"2020","unstructured":"Andreou AP, Fuccaro M, Lambru G. The role of erenumab in the treatment of migraine. Ther Adv Neurol Disord. 2020, 13:1756286420927119. 10.1177\/1756286420927119","journal-title":"Ther Adv Neurol Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786","article-title":"ARISE: a phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick DW","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, et al.. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018, 38:1026-37. 10.1177\/0333102418759786","journal-title":"Cephalalgia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby PJ","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, et al.. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017, 377:2123-32. 10.1056\/NEJMoa1705848","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomized, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter U","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD, Klatt J. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomized, double-blind, placebo-controlled, phase 3b study. Lancet. 2018, 392:2280-7. 10.1016\/S0140-6736(18)32534-0","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30322-3","article-title":"Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"17","author":"Stovner LJ","year":"2018","unstructured":"Stovner LJ, Nichols E, Steiner TJ, et al.. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018, 17:954-76. 10.1016\/S1474-4422(18)30322-3","journal-title":"Lancet Neurol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-02710-5","article-title":"Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE","volume":"22","author":"Alsaadi T","year":"2022","unstructured":"Alsaadi T, Noori S, Varakian R, Youssef S, Almadani A. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE. BMC Neurol. 2022, 22:221. 10.1186\/s12883-022-02710-5","journal-title":"BMC Neurol"},{"key":"ref12","unstructured":"IBM SPSS Statistics for Windows, Version 28.0. (2021). https.\/\/www.ibm.com\/docs\/en\/spss-statistics\/28.0.0."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01480-2","article-title":"Does MIDAS reduction at 3\u00a0months predict the outcome of erenumab treatment? A real-world, open-label trial","volume":"23","author":"De Icco R","year":"2022","unstructured":"De Icco R, Vaghi G, Allena M, et al.. Does MIDAS reduction at 3\u00a0months predict the outcome of erenumab treatment? A real-world, open-label trial. J Headache Pain. 2022, 23:123. 10.1186\/s10194-022-01480-2","journal-title":"J Headache Pain"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01069-1","article-title":"Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety","volume":"79","author":"Lattanzi S","year":"2019","unstructured":"Lattanzi S, Brigo F, Trinka E, Vernieri F, Corradetti T, Dobran M, Silvestrini M. Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety. Drugs. 2019, 79:417-31. 10.1007\/s40265-019-01069-1","journal-title":"Drugs"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018483","article-title":"Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials","volume":"98","author":"Zhu C","year":"2019","unstructured":"Zhu C, Guan J, Xiao H, Luo W, Tong R. Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials. Medicine (Baltimore). 2019, 98:e18483. 10.1097\/MD.0000000000018483","journal-title":"Medicine (Baltimore)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/281576-impact-of-erenumab-on-migraine-disability-a-three-month-midas-migraine-disability-assessment-scale-score-analysis-at-dubai-health-facilities","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,18]],"date-time":"2024-08-18T08:47:02Z","timestamp":1723970822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/281576-impact-of-erenumab-on-migraine-disability-a-three-month-midas-migraine-disability-assessment-scale-score-analysis-at-dubai-health-facilities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,18]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.67113","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,18]]}}}